23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to ...
For its internal medicines initiatives, the business has started looking for strategic substitutes including possible asset sales or licencing deals. Unless a clear agreement is achieved or legal ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...
The analysis of strategic alternatives will include an assessment of various possible scenarios, including but not limited to raising additional capital or attracting a strategic investor ...
CEO Anne Wojcicki last spring proposed buying out the company and taking it private. Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback